Jazz Pharmaceuticals’ zanidatamab shows promising results in HER2-positive biliary tract cancer

Pallavi Madhiraju- June 2, 2024 0

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has released pivotal new data from its Phase 2b HERIZON-BTC-01 clinical trial assessing zanidatamab in previously treated HER2-positive biliary tract ... Read More